3 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 terminated. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 3, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Unresectable Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Unresectable Head and Neck Squamous Cell Carcinoma trials Research Report on Unresectable Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy - Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-09 | 2023-09-13 | |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 BNT113, Pembrolizumab - Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer | Phase 2 / Phase 3 | Active not recruiting | BioNTech SE | 358 | 2021-01-07 | 2026-10-28 |
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat ImmunoPulse, Epacadostat, Pembrolizumab - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Chase Heaton, MD | 14 | 2019-05-02 | 2023-05-09 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Cabozantinib, Pembrolizumab - Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Emory University | 36 | 2018-09-18 | 2026-01-23 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Cetuximab, Edodekin alfa, Laboratory Biomarker Analysis - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2011-10-26 | 2026-07-29 |
Squamous Cell Carcinoma of Head and Neck (7) · Neoplasm Metastasis (3) · Carcinoma, Merkel Cell (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Melanoma (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinosarcoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Colorectal Neoplasms (1)
Carcinoma (7) · Carcinoma, Squamous Cell (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Neoplasms, Glandular and Epithelial (7) · Head and Neck Neoplasms (6) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Neuroendocrine (2) · DNA Virus Infections (2)
pembrolizumab (5) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · (225)Ac-DOTA-c(RGDyK) (1) · Biopsy (1) · Cetuximab (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Electroporation (1) · Electroporation Therapies (1) · Immunoglobulin G (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Nivolumab (1) · Radiosurgery (1)
BioNTech SE (1) · Chase Heaton, MD (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (5) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Mexico (1)
Chase Heaton, MD (1) · Jack Phan, MD (1) · Nabil F. Saba, MD (1) · Shailender Bhatia, MD (1) · William E Carson (1) · Yanyan Lou, MD, PhD (1)
N01CM00070 (1), P30CA016058 (1), P30CA138292 (1), U01CA076576 (1), UM1CA186712 (1)